IP Library Granted Patent US 7,273,870
Granted Patent B2
US 7,273,870 · App. 11/071,824 · Granted Sep 25, 2007

Stabilized difloxacin injectable solution

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,273,870
App. No.
11/071,824
Granted
Sep 25, 2007
Kind
B2
Abstract

An antibacterial formulation suitable for injection into animals containing approximately 2-10% w/v difloxacin HCl, L-arginine base, propylene glycol, ethanol and/or benzyl alcohol, and water. The formulation is a solution having a pH of form 9 to 10. The formulation produces little or no tissue damage or irritation at the injection site.

Claims (5)

1. A process for preparing a pharmaceutical formulation containing difloxacin, said process comprising simultaneously dissolving ditloxacin HCl and L-arginine base in a mixture of water, ethanol, propylene glycol, and optionally benzyl alcohol, at a pH of from 9 to 10 and at a temperature in the approximate range of 10-30° C., wherein on a weight-to-volume basis the free base difloxacin comprises about 2-10%, the L-arginine comprises about 5-20%, the ethanol comprises about 5-15%, the propylene glycol comprises 20-40% and benzyl alcohol comprises 0 to 10% of the formulation.

2. The process according to claim 1 wherein the difloxacin comprises about 4-6% w/v and the L-arginine comprises about 5-15% w/v.

3. The process according to claim 2 further comprising adjusting the pH to within the range of 9.1 to 9.6 by adding an inorganic base or acid.

4. The process according to claim 3 wherein said inorganic base is potassium hydroxide.

5. The process according to claim 3 wherein the difloxacin comprises about 5%, the L-arginine comprises about 10%, the ethanol comprises about 10%, the propylene glycol comprises about 30% and the benzyl alcohol comprises about 5% of the formulation on a weight-to-volume basis.